Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia

Panagiotis Ntziachristos, Aristotelis Tsirigos (), G. Grant Welstead, Thomas Trimarchi, Sofia Bakogianni, Luyao Xu, Evangelia Loizou, Linda Holmfeldt, Alexandros Strikoudis, Bryan King, Jasper Mullenders, Jared Becksfort, Jelena Nedjic, Elisabeth Paietta, Martin S. Tallman, Jacob M. Rowe, Giovanni Tonon, Takashi Satoh, Laurens Kruidenier, Rab Prinjha, Shizuo Akira, Pieter Van Vlierberghe, Adolfo A. Ferrando, Rudolf Jaenisch, Charles G. Mullighan () and Iannis Aifantis ()
Additional contact information
Panagiotis Ntziachristos: NYU School of Medicine
Aristotelis Tsirigos: NYU School of Medicine
G. Grant Welstead: Whitehead Institute for Biomedical Research
Thomas Trimarchi: NYU School of Medicine
Sofia Bakogianni: NYU School of Medicine
Luyao Xu: Institute for Cancer Genetics, Columbia University Medical Center
Evangelia Loizou: NYU School of Medicine
Linda Holmfeldt: St. Jude Children’s Research Hospital
Alexandros Strikoudis: NYU School of Medicine
Bryan King: NYU School of Medicine
Jasper Mullenders: NYU School of Medicine
Jared Becksfort: St. Jude Children’s Research Hospital
Jelena Nedjic: NYU School of Medicine
Elisabeth Paietta: Montefiore Medical Center North, Bronx
Martin S. Tallman: Memorial Sloan Kettering Cancer Center
Jacob M. Rowe: Technion, Israel Institute of Technology
Giovanni Tonon: Functional Genomics of Cancer Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, 20132 Milan, Italy
Takashi Satoh: Laboratory of Host Defense, WPI Immunology Frontier Research Center (WPI IFReC), Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Japan
Laurens Kruidenier: Epinova DPU, Immuno-Inflammation Therapy Area, GlaxoSmithKline R&D, Medicines Research Centre, GunnelsWood Road, Stevenage SG1 2NY, UK
Rab Prinjha: Epinova DPU, Immuno-Inflammation Therapy Area, GlaxoSmithKline R&D, Medicines Research Centre, GunnelsWood Road, Stevenage SG1 2NY, UK
Shizuo Akira: Laboratory of Host Defense, WPI Immunology Frontier Research Center (WPI IFReC), Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Japan
Pieter Van Vlierberghe: Institute for Cancer Genetics, Columbia University Medical Center
Adolfo A. Ferrando: Institute for Cancer Genetics, Columbia University Medical Center
Rudolf Jaenisch: Whitehead Institute for Biomedical Research
Charles G. Mullighan: St. Jude Children’s Research Hospital
Iannis Aifantis: NYU School of Medicine

Nature, 2014, vol. 514, issue 7523, 513-517

Abstract: T-cell acute lymphoblastic leukaemia (T-ALL) is a haematological malignancy with a poor prognosis and no available targeted therapies; now two histone H3 lysine 27 demethylases, JMJD3 and UTX, are shown to have contrasting roles in human T-ALL cells and a mouse model of the disease, and a small molecule demethylase inhibitor is found to inhibit the growth of T-ALL cell lines, introducing a potential therapeutic avenue for acute leukaemia.

Date: 2014
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/nature13605 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:514:y:2014:i:7523:d:10.1038_nature13605

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature13605

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().